ICON plc is a global provider of outsourced drug development services and offers a flexible partnership model for biotechs, acting as a fully externalised project development team. We offer a full range of clinical, consulting and commercial services.
Products, services, technology
Consulting & Advisory services - Asset Development, Regulatory Affairs, Commercial Positioning, Tailored clinical development - over 8,000 employees worldwide dedicated exclusively to biotech clients, Therapeutic expertise - including CGT and novel first-in-class immunotherapies.
ICON can assist biotechs in establishing key clinical development processes and infrastructure internally, including:
Due diligence and asset valuation processes, Asset development consulting, Quality management systems and standard operating procedures, Medical safety boards.
At ICON our reputation is built on enduring partnerships that are driven to advance medicine and make a difference in the world. Since our inception in 1990, we’ve partnered with biotech clients, collaborating, innovating, and finding new ways together to improve outcomes.
ICON brings a suite of capabilities, expertise and technology to augment your operations, increase R&D efficiencies and improve site engagement to access patient populations and deliver timelines and milestones.